MiR-217 enhances chemosensitivity of AML cells to doxorubicin by targeting KRAS [163], while miR-204 potentiates the sensitivity of acute promyelocytic leukemia (APL) cells to arsenic trioxide (ATO) [164]. Here, KRAS is linked to acute promyelocytic leukemia.